Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

v3.22.2.2
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Jul. 31, 2022
Accounting Policies [Abstract]  
Schedule of net accounts receivable by segment
    July 31, 2022     July 31, 2021  
Net accounts receivable by segment   Amount     %     Amount     %  
Clinical Labs (by billing category)                        
Third party payers   $ 2,647       40     $ 2,195       36  
Patient self-pay     2,779       41       2,007       33  
Medicare     768       11       1,122       19  
HMO’s     560       8       692       12  
Total Clinical Labs     6,754       100 %     6,016       100 %
Total Life Sciences     4,762               4,182          
Total accounts receivable – net   $ 11,516             $ 10,198          

 
Schedule of basic and diluted net income (loss) per share
    2022     2021     2020  
Net (loss) income   $ (18,261 )   $ 7,875     $ (28,520 )
                         
Weighted-average common shares outstanding – basic     48,594       48,191       47,696  
Add: effect of dilutive stock options and restricted stock    
—
       134      
—
  
Weighted-average common shares outstanding – diluted     48,594       48,325       47,696  
                         
Net (loss) income per share – basic   $ (0.38 )   $ 0.16     $ (0.60 )
Net (loss) income per share – diluted   $ (0.38 )   $ 0.16     $ (0.60 )

 
Schedule of expenses related share-based payment arrangements
    2022     2021     2020  
Cost of clinical laboratory services   $ 14     $ 93     $ 46  
Selling, general and administrative     1,482       814       887  
    $ 1,496     $ 907     $ 933